CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Eicosapentaenoic acid gastro-resistant capsulesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug475 Lopinavir and Ritonavir Tablets Wiki 1.00
drug58 Arbidol Wiki 0.71

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.12
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2

This is an open-label, randomized, controlled study in hospitalized subjects with confirmed SARS-CoV-2.

NCT04335032 SARS-CoV-2 Drug: Eicosapentaenoic acid gastro-resistant capsules

Primary Outcomes

Description: Time to treatment failure during the 28-day treatment period. Treatment failure is defined as additional or alternative treatment required, or intubation and invasive ventilation, or transfer to intensive care unit, or death.

Measure: Evaluation of EPA-FFA efficacy compared to standard of care

Time: 28 days

Secondary Outcomes

Description: Time to (in days) and number of days with oxygen saturation >95% without oxygen inhalation during the 28-day treatment period

Measure: Increase in oxygen saturation

Time: 28 days

Description: Time to (in days) and number of days with PaO2/FiO2 >300mmHg without oxygen inhalation during the 28-day treatment period

Measure: PaO2/FiO2 >300mmHg increase

Time: 28 days

Description: Change in IL-6 level during the 28-day treatment period

Measure: Reduction of IL-6

Time: 28 days

Description: To determine whether EPA-FFA gastro-resistant capsules decreases mortality rate during the study.

Measure: Mortality rate reduction

Time: throughout the study, about 3 months

Description: To determine whether EPA-FFA gastro-resistant capsules decreases ICU days during the study.

Measure: Reduction in ICU stays

Time: throughout the study, about 3 months

Description: To determine whether EPA-FFA gastro-resistant capsules decreases hospitalisation days during the study

Measure: Reducing hospitalisation days

Time: throughout the study, about 3 months

Description: To determine whether EPA-FFA gastro-resistant capsules decreases the need for invasive mechanical ventilation during the study

Measure: reduction in need for mechanical ventilation

Time: throughout the study, about 3 months

Description: Time to (in days) and number of days with fever normalization < 36.6°C armpit, < 37.2°C oral, < 37.8°C rectal, during the 28-day treatment period

Measure: Fever reduction

Time: 28 days

Other Outcomes

Description: To evaluate the safety of EPA-FFA gastro-resistant capsules in the treatment of COVID-19 (SARS-CoV-2) by assessing subjects clinical lab parameters and vital signs, and the number and proportion of subjects with AEs.

Measure: Safety - Vitals, AEs and Clinical lab parameters

Time: throughout the study, about 3 months

No related HPO nodes (Using clinical trials)